Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board," said Robert Radie, chairman, and chief executive officer of Neuraptive. "His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
PHILADELPHIA -- Businesswire -- Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.
“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."
Dr. Ruffolo has over 40 years of research and development experience and is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories. He earned his Ph.D. in Pharmacology and his B.S. in Pharmacy from The Ohio State University.
About Neuraptive
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005443/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Neuraptive Therapeutics, Inc.
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 김명중 사진작가와 프로쉬 ‘22세기 유물전’ 개최 - 뉴스와이어
- 송도국제캠핑장, 바베큐장 ‘더 팜 송도’ 그랜드 오픈 - 뉴스와이어
- AI 버추얼 아티스트 수비, 디지털 싱글 ‘SUNCREAM’ 콘셉트 포토 공개 - 뉴스와이어
- 벼룩시장 조사, 직장인 10명 중 9명 ‘고용불안 느낀다’ - 뉴스와이어
- HL만도 주차로봇 ‘파키’ 인천국제공항서 발렛파킹 실증 운영 - 뉴스와이어
- 증가하는 청년 자살… 청년이 직접 자살예방 활동을 하는 ‘청년 자살예방 서포터즈 3기’ 출발
- 아모레퍼시픽, SBTi로부터 넷제로 목표 승인 획득 - 뉴스와이어
- ‘카드캡터 체리: 추억의 열쇠’ 국내 앱마켓 인기 게임 차트 1위 등극 - 뉴스와이어
- ‘역대 최대 115만여 명 참가’ 제21회 서울국제환경영화제 성공적 마무리 - 뉴스와이어
- 영진약품, Dx&Vx 와 전략적 MOU 체결 혁신신약 포트폴리오 강화 나서 - 뉴스와이어